BioMedNewsBreaks

TuesdayApr 19, 2022 12:31 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation in Upcoming Conferences

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, will be involved in several conferences in April and May. Company management will be participating at the Benzinga Spring Cannabis Capital Conference, scheduled for April 20–21, 2022, in Miami Beach, Florida. InMed executives will be meeting virtually with institutions and industry representatives. Company executives will also be at Canaccord Genuity’s sixth annual Global Cannabis Conference held on May 11, 2022. A recording of the company’s presentation will be available on InMed’s investor relations website following the event. Company leaders will also be available for…

Continue Reading

MondayApr 18, 2022 2:35 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expanding Rare Cannabinoid Manufacturing Scale

InMed Pharmaceuticals (NASDAQ: INM), a rare cannabinoid drug developer, is expanding its product manufacturing scale, thanks largely to the acquisition of consumer-focused rare cannabinoids manufacturer BayMedica last year. “InMed’s most-recent Q2 financial statement reported revenues of $0.3 million from commercial sales of cannabichromene (‘CBC’) to the health and wellness market following the BayMedica acquisition. Since January, the company has also been selling cannabicitran (‘CBT’) to the health and wellness market on a B2B basis,” a recent article reads. “The company’s forward-looking focus on bringing new cannabinoid products to commercial scale anticipates scales of cannabidivarin (‘CBDV’) and tetrahydrocannabivarin (‘THCV’) in the…

Continue Reading

ThursdayApr 14, 2022 9:33 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), was spotlighted in an episode of the Power Play by the Market Herald. Cybin CEO Doug Drysdale talked with host Dave Jackson about the company’s recent positive results from its CYB004 pharmacokinetic study. The company announced that the study produced positive preclinical data demonstrating that when inhaled, Cybin’s deuterated dimethyltryptamine (“DMT”) molecule indicated advantages, such as a longer duration of action and improved bioavailability, over both IV DMT and inhaled DMT. Power Play interviews with company executives offer investors a quick snapshot of an array of…

Continue Reading

WednesdayApr 13, 2022 11:33 am

BioMedNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Significant Advantages over IV and Inhaled DMT in Pharmacokinetic Study

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced positive preclinical data from a pharmacokinetic study evaluating its proprietary deuterated dimethyltryptamine (“DMT”) molecule, CYB004, delivered via inhalation. According to the announcement, inhaled CYB004 demonstrated significant advantages over both intravenous and inhaled DMT, including longer duration of action and improved bioavailability. The study also demonstrated that inhaled CYB004 showed a similar dose profile and onset of effect to IV DMT. “In many studies, DMT has shown to be a promising and effective psychedelic for the treatment of mental health issues. However, known side…

Continue Reading

TuesdayApr 12, 2022 2:39 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Names New Director, CEO

RYAH Group (CSE: RYAH), a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry, has announced that its board of directors has nominated Dr. David R. Richards, PhD, FIoD, FRSA, CPsych, as a new director and the company’s chief executive officer. Richards comes to the new positions with impressive experience, including serving in leadership roles at Nortel Networks' GM Global Data; GM Global Supercarriers; GM UK Switching; and Global ThinkQuest Champion at Oracle's Education Foundation. He has served as CEO of Ellis Jones Solicitors, executive director of…

Continue Reading

TuesdayApr 12, 2022 12:27 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in Upcoming Virtual Investor Event

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be part of a moderated fireside chat during the Virtual Investor Glioblastoma Multiforme (“GBM”) Spotlight event on April 14, 2022. The chat is scheduled for 11:30 a.m. ET and will include CNS Pharmaceuticals management team members, including CEO John Climaco, along with opinion leader Samuel A. Goldlust, MD. The focus of the chat will be GBM and the work that CNS Pharmaceuticals is doing to advance Berubicin, its novel anthracycline and the first anthracycline to…

Continue Reading

FridayApr 08, 2022 1:29 pm

BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Working to Capitalize on Psychedelics Therapeutics Market’s Growth

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. A recent article discusses the company’s efforts to lead the charge toward developing novel psychedelic and non-psychedelic molecules for medical use. “Its research and development efforts have focused on compounds that can enable safer and more effective treatments for patients dealing with mental health and addiction disorders with unmet needs,” the article reads. “Mydecine, through its research, has positioned itself to capitalize on the opportunities in the industry, particularly with regards to psychedelic medicine for the treatment…

Continue Reading

FridayApr 08, 2022 11:39 am

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Further Strengthens Long-Term IP Position of Psychedelic-Based Programs

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that the World Intellectual Property Organization (“WIPO”) published an international patent application covering a range of inhalation delivery methods across multiple psychedelic molecules (Patent Cooperation Treaty (‘PCT’) patent application no.PCT/EP2021/077057). This further strengthens the company’s long-term intellectual property (“IP”) position of psychedelic-based programs. “The publication of this PCT patent application demonstrates our continued commitment to discovering and developing new psychedelic-based treatment options, in addition to identifying and combining potentially improved and well-controlled delivery systems with these clinical candidates,” said Cybin CEO Doug Drysdale.…

Continue Reading

ThursdayApr 07, 2022 2:22 pm

BioMedNewsBreaks – Why Silo Pharma Inc. (SILO) Is ‘One to Watch’

Silo Pharma (OTCQB: SILO) is committed to developing innovative solutions to address various underserved conditions such as post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare neurological disorders as part of its focus on merging traditional therapeutics with psychedelic research. “Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves,” a recent article reads. Silo Pharma is involved in a sponsored study with Maastricht University…

Continue Reading

WednesdayApr 06, 2022 1:05 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Approval from France EC and ANSM Competent Authority for Potentially Pivotal Study of Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced its receipt of approval from the National Agency for the Safety of Medicine and Health Products (“ANSM”) Competent Authority and from the People Protection Ethics Committee (“EC”) SUD-EST III (“CPP Sud-Est III”) in France for the company's potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types of brain cancer. “Access to patients is the lifeblood of any clinical study and this…

Continue Reading